Urelumab

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
Read more
€0.00 (tax incl.)
Reference:
HY-P99055
Product Details
HY-P99055

Data sheet

Size
Multiple sizes
Reactivity
Others
Application
COVID-19-immunoregulation
CAS
934823-49-1

Menu

Settings